Finoriq research workspace
ABEONA THERAPEUTICS INC. (ABEO) SEC Filings & Filing Highlights
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell. Review ABEO SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
- Company
- ABEONA THERAPEUTICS INC. (ABEO)
- Ticker
- ABEO
- Market Cap
- $368.2M
- Latest Price
- $6.46
- Industry
- Biotech & Pharma
ABEONA THERAPEUTICS INC. (ABEO) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for ABEONA THERAPEUTICS INC. (ABEO).
| Event | Form | Date |
|---|---|---|
| The annual meeting of stockholders of Abeona Therapeutics Inc. was held virtually on June 12, 2...The annual meeting of stockholders of Abeona Therapeutics Inc. (the “Company”) was held virtually on June 12, 2026, at 9:00 a.m., Eastern T... | 8-K5.07 | 2026-06-12 |
| On June 11, 2026, Michael Amoroso resigned as a member of the Board of Directors (the “Board”)...On June 11, 2026, Michael Amoroso resigned as a member of the Board of Directors (the “Board”) of Abeona Therapeutics Inc. (the “Company”)... | 8-K5.02 | 2026-06-12 |
| Regulation FDRegulation FD | 8-K7.01 | 2026-06-10 |
| Abeona Therapeutics IncOn June 3, 2026, Abeona Therapeutics Inc. (the “Company”) participated in a pre-Investigational New Drug application (“Pre-IND”) meeting wi... | 8-K8.01 | 2026-06-04 |
| Abeona Therapeutics® Reports First Quarter 2026 ResultsAbeona Therapeutics® Reports First Quarter 2026 Results | 8-K2.02 | 2026-05-13 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.